Hydrochlorothiazide and the Risk of Skin Cancer

Hydrochlorothiazide, one of the most widely prescribed blood pressure medications in the world, is associated with a higher risk of certain skin cancers, but the risk depends heavily on how much of the drug a person takes over their lifetime and which type of skin cancer you’re talking about. The strongest and most consistent evidence points to squamous cell carcinoma, especially of the skin and lips, in people who have taken high cumulative doses over many years. For casual or short-term use, the signal largely disappears.

Which Types of Skin Cancer Are Linked to Hydrochlorothiazide

Not all skin cancers respond equally to hydrochlorothiazide exposure, and this distinction matters more than many summaries let on. The clearest link is with squamous cell carcinoma (SCC), the second most common form of skin cancer. A large Danish case-control study found that people who had used at least 50,000 mg of HCTZ cumulatively had roughly four times the odds of developing SCC compared to non-users, and the risk climbed steeply with higher doses.¹ A systematic review and meta-analysis confirmed this pattern, finding a consistent association between HCTZ use and both cutaneous and lip squamous cell carcinoma across multiple studies.²

Basal cell carcinoma (BCC), the most common skin cancer overall, shows a much weaker relationship. The same Danish study found only a modest increase in BCC risk at high cumulative doses, with odds roughly one and a half times higher in the heaviest users.¹ Another study found no increased BCC risk at all, reporting a hazard ratio of essentially 1.0.³ So whether HCTZ meaningfully raises BCC risk remains genuinely uncertain.

Melanoma, the deadliest form of skin cancer, has the weakest and most contradictory evidence. One study found no increased melanoma risk with HCTZ use and even a slightly protective (though statistically non-significant) point estimate.³ A Spanish study using two separate databases found inconsistent results for melanoma: one database showed a modestly increased risk while the other showed none.⁴ A large U.S. analysis comparing HCTZ to ACE inhibitors found hazard ratios for melanoma hovering around 1.0 across multiple cohorts, meaning no meaningful increase.⁵ At this point, the evidence does not support a meaningful melanoma connection.

The Dose-Response Relationship

If there is one consistent finding across the research, it’s that cumulative dose is the critical variable. People who take HCTZ for a few months or even a few years at standard doses generally don’t show a detectable increase in skin cancer risk. A Dutch cohort study found that the risk of any skin cancer was not significantly increased among general HCTZ users. Only when cumulative exposure crossed about 125,000 mg did the association become strong and clear, with an adjusted hazard ratio above 5 for any skin cancer and above 7 for keratinocyte carcinomas specifically.⁶

To put that in practical terms, standard HCTZ dosing for blood pressure is typically 12.5 to 25 mg per day. At 25 mg daily, reaching 125,000 mg would take about 14 years. At 50 mg daily (a higher but still common dose), you’d get there in roughly 7 years. The Danish study showed a stepwise increase in SCC risk across dose categories, with the highest group (200,000 mg or more cumulative) facing odds about seven times higher than non-users.¹ This dose-dependent pattern is part of what makes the association biologically plausible rather than just a statistical quirk.

That said, even at high cumulative doses, the absolute risk remains modest for any individual patient. Squamous cell carcinoma is already quite common in fair-skinned older adults regardless of medication use, so a relative increase of several-fold is layered on top of a risk that varies enormously with sun exposure, skin type, and age.

Lip Cancer Deserves Special Attention

Among all the cancer sites studied, the lip stands out. Squamous cell carcinoma of the lip shows an unusually strong association with HCTZ, which makes biological sense because lips receive direct sun exposure and lack the melanin protection that covers most other skin. A Danish study found that even “ever-use” of HCTZ roughly doubled the odds of lip SCC, and high use (25,000 mg or more) pushed the odds to nearly four times higher. At the heaviest cumulative doses (100,000 mg or more), the odds ratio jumped to about 7.7.⁷

Lip cancer is uncommon in the general population, so even a sevenfold increase translates to a low absolute number of cases. But the strength and consistency of the signal are noteworthy, and it’s a finding that has practical implications: if you’re a long-term HCTZ user, wearing lip balm with SPF protection and paying attention to persistent sores or changes on the lips is a reasonable precaution that costs nothing.

Why HCTZ Makes Skin More Vulnerable to Sunlight

HCTZ has been known to be a photosensitizing drug for decades. People on it sometimes get sunburns more easily or develop a rash after sun exposure. The question is whether that photosensitization goes deep enough to promote cancer, and the lab evidence increasingly says yes.

When human skin cells (keratinocytes) were exposed to UVA radiation in the presence of HCTZ at concentrations you’d see in a person taking a normal dose, the drug amplified the DNA damage produced by the UV light. Researchers observed more double-strand breaks, more oxidative damage to both DNA and proteins, and impaired activity of a key DNA repair enzyme called OGG1.⁸ In mouse models, HCTZ significantly boosted the formation of specific UV-induced DNA damage products called cyclobutane pyrimidine dimers, especially in animals with compromised DNA repair capacity.⁹

More recently, experiments on actual human skin biopsies showed that HCTZ-treated tissue responded to even low-dose UVA by activating the p53 tumor-suppressor protein, a molecular alarm system that fires when cells detect trouble. The drug-plus-UV combination triggered p53 stabilization and nuclear translocation at radiation doses that didn’t do so in untreated tissue. At higher UV doses, the combination also caused overt DNA damage and switched on inflammatory gene expression.¹⁰ The upshot is that HCTZ appears to lower the threshold at which sunlight begins causing the kind of cellular damage that, over years, can accumulate into cancer. It’s not that the drug causes cancer on its own; it’s that it makes everyday UV exposure more dangerous than it would otherwise be.

How HCTZ Compares to Other Blood Pressure Drugs

A natural question for anyone taking HCTZ is whether they’d be better off on a different medication. The picture here is mixed and worth exploring carefully.

A review of 13 observational studies looking at various thiazide and thiazide-like diuretics found positive skin cancer associations across the class, with increased risks ranging from a few percent for some drug-cancer combinations up to a roughly fourfold increase for thiazides and SCC.¹¹ Chlorthalidone, the main thiazide-like alternative to HCTZ, showed a similar pattern of increased keratinocyte carcinoma rates in White populations.¹² So switching from HCTZ to chlorthalidone may not resolve the photosensitivity concern.

What about entirely different drug classes? A Canadian population-based study found that associations between non-thiazide antihypertensives and skin cancer were small, inconsistent, or statistically non-significant.¹³ A more recent registry-based study did find very small BCC risk increases (on the order of 7 to 9 percent) for several antihypertensive classes, including ARBs, calcium channel blockers, and beta-blockers.¹⁴ Increases that small are hard to distinguish from residual confounding, and they’re an order of magnitude smaller than the SCC risk seen with heavy HCTZ use. In practice, HCTZ carries the most notable signal, and the thiazide class more broadly appears to carry more photosensitization risk than other blood pressure drug families.

A large U.S. analysis comparing HCTZ directly to ACE inhibitors found hazard ratios for nonmelanoma skin cancer that were close to 1.0 across different insurance cohorts, suggesting that in a real-world American population, the difference between HCTZ and ACE inhibitors may be smaller than the European data implies.⁵ This discrepancy between European and U.S. findings is one of the more interesting and unresolved puzzles in this research area.

Geography, Skin Color, and UV Exposure

Much of the research linking HCTZ to skin cancer comes from Scandinavia and Northern Europe, where populations are overwhelmingly fair-skinned and UV exposure patterns are specific. Whether the same risks apply to people living at different latitudes, with different skin pigmentation, or with different sun habits is genuinely unclear.

The risk of nonmelanoma skin cancer is influenced by sun exposure, skin color, and genetics, and the strength of the HCTZ association may vary considerably between continents and countries.¹⁵ A global cohort study found that the increased keratinocyte carcinoma risk with both HCTZ and chlorthalidone appeared only in White populations.¹² That doesn’t necessarily mean the photosensitizing effect vanishes in darker-skinned individuals, but it does suggest that the baseline risk of UV-related skin cancer is so much lower in those populations that any HCTZ-related increment is too small to detect.

This creates a genuine clinical dilemma. HCTZ is an effective, inexpensive, widely available blood pressure medication with a decades-long track record. In countries with limited formularies or where cost matters enormously, pulling it from first-line use based on studies in Scandinavian populations may not make sense. The geographic analysis highlighted that in regions where hypertensive heart disease causes substantial disability, the cardiovascular benefit of HCTZ likely outweighs the incremental skin cancer risk, especially for non-White populations.¹⁵

Methodological Cautions Worth Knowing

The evidence here is entirely observational. No randomized trial has been designed to test whether HCTZ causes skin cancer (nor would one be ethical for that purpose). Observational studies are vulnerable to confounding: people who take HCTZ for years tend to be older, to visit doctors regularly, and to have comorbidities. Several important confounders are hard to measure in database studies. Researchers have acknowledged an inability to adjust for individual UV exposure history, Fitzpatrick skin type, and other comorbidities in many of these analyses.¹⁶

Detection bias is another concern. If HCTZ users visit dermatologists more frequently because of photosensitivity warnings on their prescription bottles, their skin cancers could be caught at higher rates than those of people on other medications, inflating the apparent association.¹⁷ This is a plausible concern because nonmelanoma skin cancers, especially superficial BCC, often go undiagnosed in people who don’t see a dermatologist regularly.

These methodological limitations don’t invalidate the findings. The dose-response relationship, the biological plausibility from lab studies, and the specificity of the signal to SCC rather than all cancers collectively all argue that there’s a real effect. But they do mean the precise magnitude of the risk increase is less certain than the headline numbers suggest, and the U.S. data showing essentially null results when HCTZ is compared head-to-head against ACE inhibitors reinforces the need for caution in interpreting the European findings as universal truths.

Prescribing Patterns Barely Budged After the Label Change

In 2020, the U.S. FDA updated the HCTZ label to include information about the potential skin cancer risk. You might expect that a cancer warning would lead doctors and patients to shift away from the drug in meaningful numbers. That largely didn’t happen. A study of prescribing trends found that the label update was associated with a statistically significant but clinically negligible monthly change in the proportion of HCTZ use, amounting to a shift of about 0.018 percent. A secondary analysis looking specifically at the proportion of HCTZ among all antihypertensive prescriptions found no significant change at all.¹⁸

This inertia has several possible explanations. HCTZ is cheap, effective, and familiar to prescribers. Many patients are on stable regimens and reluctant to switch. The absolute risk increase, even at high cumulative doses, is modest enough that most doctors and patients apparently conclude the trade-off favors continuing the medication, especially for people who aren’t at high baseline risk for skin cancer. The near-zero prescribing response also suggests that the nuances of the evidence, particularly the dose dependence and the concentration of risk in fair-skinned populations, may not be reaching clinicians in a form that prompts action for the subset of patients who genuinely are at elevated risk.

Practical Considerations for People Taking HCTZ

For someone currently on HCTZ, the research suggests a few concrete takeaways rather than a blanket reason to panic. If you’re fair-skinned, live in a high-UV environment, and have already been taking the drug for many years at moderate-to-high doses, the cumulative photosensitization effect is worth discussing with your doctor, particularly if you have other SCC risk factors like a history of sunburns, outdoor occupations, or previous skin cancers. In that scenario, switching to a non-thiazide antihypertensive may be reasonable.

If you’re darker-skinned, or if you’ve been on a low dose for a relatively short period, the available data doesn’t suggest a meaningfully increased risk. Sun protection remains sensible for all HCTZ users: broad-spectrum sunscreen, protective clothing, and SPF lip balm, which is particularly relevant given the lip cancer findings. Annual skin checks by a dermatologist are worth considering for long-term users in higher-risk groups, not out of alarm, but because early detection of SCC is straightforward and outcomes are excellent when caught early. The most important point is that HCTZ and skin cancer isn’t a binary story of “safe” or “dangerous.” It’s a question of cumulative exposure, individual risk factors, and whether cheaper alternatives would control your blood pressure equally well.

1
Journal of the American Academy of Dermatology. Hydrochlorothiazide use and risk of nonmelanoma skin cancer: A nationwide case-control study from Denmark
2
PubMed. Hydrochlorothiazide use is associated with the risk of cutaneous and lip squamous cell carcinoma: A systematic review and meta-analysis
3
PubMed. Use of Hydrochlorothiazide and Risk of Melanoma and Nonmelanoma Skin Cancer
4
PubMed. Use of hydrochlorothiazide and risk of skin cancer in a large nested case-control study in Spain
5
PubMed Central. Skin Cancer and Hydrochlorothiazide: Novel Population-Based Analyses Considering Personal Risk Factors Including Race/Ethnicity
6
PubMed Central. Chronic Use of Hydrochlorothiazide and Risk of Skin Cancer in Caucasian Adults: A PharmLines Initiative Inception Cohort Study
7
PubMed. Hydrochlorothiazide use is strongly associated with risk of lip cancer
8
PubMed Central. Hydrochlorothiazide Use and Risk of Nonmelanoma Skin Cancers: A Biological Plausibility Study
9
PubMed. Hydrochlorothiazide enhances UVA-induced DNA damage
10
Nature. Assessing phototoxic drug properties of hydrochlorothiazide using human skin biopsies
11
Journal of Hypertension. Reviewing the effects of thiazide and thiazide-like diuretics as photosensitizing drugs on the risk of skin cancer
12
PubMed. Risk of skin cancer from hydrochlorothiazide and other diuretics across races: A global cohort study
13
CMAJ. Association between antihypertensive medications and risk of skin cancer in people older than 65 years: a population-based study
14
PubMed Central. Antihypertensive Medication as a Risk Factor For Basal Cell Carcinoma: A Nationwide Registry-based Case-control Study
15
American Journal of Hypertension. Geographical Differences in Hydrochlorothiazide Associated Risk of Skin Cancer Balanced Against Disability Related to Hypertensive Heart Disease
16
PubMed. Association between hydrochlorothiazide and the risk of in situ and invasive squamous cell skin carcinoma and basal cell carcinoma: A population-based case-control study
17
JNCI Cancer Spectrum. Risk of Nonmelanoma Skin Cancer in Association With Use of Hydrochlorothiazide-Containing Products in the United States
18
PubMed Central / Wiley Online Library. Use of Hydrochlorothiazide in the United States Following Label Update About Skin Cancer Risk